Page 157 - Glucose Monitoring Devices

158 CHAPTER 7 Clinical impact of CGM use

[71] Bergenstal RM, et al. Effectiveness of sensor-augmented insulin-pump therapy in type
1 diabetes. The New England Journal of Medicine 2010;363:311e20.
[72] Bergenstal RM, et al. Threshold-based insulin-pump interruption for reduction of
hypoglycemia. The New England Journal of Medicine 2013;369:224e32.
[72a] Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial
of closed-loop control in type 1 diabetes. N. Engl. J. Med. 2019;381:1707e17.
[73] van den Berghe G, et al. Intensive insulin therapy in critically ill patients. The New
England Journal of Medicine 2001;345:1359e67.
[74] NICE-SUGAR Study Investigators, et al. Intensive versus conventional glucose con-
trol in critically ill patients. The New England Journal of Medicine 2009;360:
1283e97.
[75] Levitt DL, Silver KD, Spanakis EK. Inpatient continuous glucose monitoring and gly-
cemic outcomes. Journal of Diabetes Science and Technology 2017;11:1028e35.